Vitamin D Deficiency and Insulin Resistance

Mechanisms and Associations

The American College of Endocrinology suggests that vitamin D increases glucose transport in adipocytes through enhanced translocation of GLUT4, improving insulin sensitivity at the cellular level 1
The Endocrine Society indicates that the active form of vitamin D (1-25(OH)2D) suppresses the expression of multiple inflammatory cytokines, including IL-6, IL-1β, and IL-8, in preadipocytes and adipocytes, reducing adipose tissue inflammation that contributes to insulin resistance 1, 2
The presence of vitamin D receptors (VDR) in key tissues, including the pancreas, skeletal muscle, and adipose tissue, provides the mechanistic interface for these metabolic effects 2

The American Heart Association notes that patients with obesity typically demonstrate low levels of 25(OH)D that correlate inversely with body mass index (BMI) and adiposity 1, 2
Excess adipose tissue serves as a reservoir for lipophilic forms of vitamin D, altering the kinetics between this depot and circulation, contributing to low circulating levels 1, 2
The prevalence of vitamin D insufficiency is 35% higher in individuals with obesity compared to those with normal weight 1, 2
After administering equal doses of vitamin D, 25(OH)D levels were approximately 15.2 ng/mL lower in patients with obesity compared to eutrophic individuals 1, 2

The American College of Physicians recommends evaluating vitamin D levels in patients with established insulin resistance who have risk factors for deficiency, including reduced sun exposure, darker skin pigmentation, advanced age, inflammatory bowel disease, malabsorptive conditions, or living at high latitudes 3
If vitamin D deficiency (≤15 ng/mL or ≤37.5 nmol/L) is documented, treatment should follow standard protocols for the deficiency itself, not for specific metabolic benefit, with ergocalciferol 50,000 UI weekly for 8-12 weeks, followed by maintenance therapy of 800-1,000 UI daily 4
In patients with obesity, daily doses of 4,000 UI may be necessary to prevent insufficiency 1, 2
Serum calcium and phosphorus should be monitored every 3 months during treatment 4